In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

Abstract

The International Network for Optimal Resistance Monitoring (INFORM) global surveillance program collected clinical isolates of Enterobacteriaceae (n ϭ 7,665) and Pseudomonas aeruginosa (n ϭ 1,794) from 26 medical centers in six Latin American countries from 2012 to 2015. The in vitro activity of ceftazidime-avibactam and comparators was determined for the isolates using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method. Enterobacteriaceae were highly susceptible (99.7%) to ceftazidime-avibactam, including 99.9% of metallo-␤-lactamase (MBL)-negative isolates; 87.4% of all P. aeruginosa isolates and 92.8% of MBL-negative isolates were susceptible to ceftazidime-avibactam. Susceptibility to ceftazidime-avibactam ranged from 99.4% to 100% for Enterobacteriaceae and from 79.1% to 94.7% for P. aeruginosa when isolates were analyzed by country of origin. Ceftazidime-avibactam inhibited 99.6% to 100% of Enterobacteriaceae isolates that carried serine ␤-lactamases, including extended-spectrum ␤-lactamases (ESBLs), AmpC cephalosporinases, and carbapenemases (KPC and OXA-48-like) as well as 99.7%, 99.6%, 99.5%, and 99.2% of MBL-negative isolatesdemonstratingceftazidime-nonsusceptible,multidrug-resistant(MDR),meropenem-nonsusceptible, and colistin-resistant phenotypes, respectively. Among carbapenem-nonsusceptible isolates of P. aeruginosa (n ϭ 750), 14.7% carried MBLs with or without additional acquired serine ␤-lactamases, while in the majority of isolates (70.0%), no acquired ␤-lactamase was identified. Ceftazidime-avibactam inhibited 89.5% of carbapenem-nonsusceptible P. aeruginosa isolates in which no acquired ␤-lactamase was detected. Overall, clinical isolates of Enterobacteriaceae collected in Latin America from 2012 to 2015 were highly susceptible to ceftazidime-avibactam, including isolates that exhibited resistance to ceftazidime, meropenem, colistin, or an MDR phenotype. Country-specific variations were noted in the susceptibility of P. aeruginosa isolates to ceftazidime-avibactam.

In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries

“…Of the evaluated strains, 0.8% were resistant to MEM. Similarly, Karlowsky et al [9] evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales and P. aeruginosa collected between 2012 and 2015 from six Latin American countries (Argentina, Brazil, Chile, Colombia, Mexico and Venezuela). In this study, CZA was active against 99.7% of 7665 Enterobacterales, which is similar to our findings.…”

Current treatment options for infections caused by carbapenem-resistant Enterobacteriaceae in patients with hematological malignancies

“…По данным мно гоцентрового эпидемиологического исследования МАРАФОН, цефтазидимавибактам по сравнению с другими антибиотиками проявлял наиболее высо кую чувствительность среди клинически значимых энтеробактерий, выделенных от больных в стациона рах России, которая составила 96,5 %, среди карба пенемазопродуцирующих бактерий, включая проду центы МБЛ, -79,6 % [12]. По результатам работ ученых из США чувствительность энтеробактерий с продук цией карбапенемаз групп KPC к цефтазидимуавибак таму составила 98,7-99,6 %, групп OXA48 -98,5-100 % [49,50]. Все штаммы энтеробактерий с продукцией OXA48 (n = 76), выделенные из гемокультуры от боль ных с опухолями системы крови в многоцентровом исследовании российских клиник, были чувствитель ными к цефтазидимуавибактаму (собственные не опубликованные данные).…”

<p>First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against <em>Pseudomonas aeruginosa</em> Isolated from Patients with Urinary Tract Infection in Tehran, Iran</p>

“…Furthermore, avibactam has shown a more inhibitory effect in comparison to the common β-lactamase inhibitors such as clavulanic acid, sulbactam, and tazobactam. 5 Ceftolozane-tazobactam (C/T) is a mixture of a new cephalosporin merged with a β-lactam β-lactamase inhibitor called tazobactam. Tazobactam irreversibly binds to the active site of β-lactamases and protects ceftolozane from destruction by the majority of β-lactamases such as ESBLs enzymes; however, it does not improve its activity against pathogens such as P. aeruginosa.…”